Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like you got your $1.57 scalp on PRKR beach
VRNG
Web Version
Forward
VRINGO FILES LAWSUIT AGAINST ZTE IN ROMANIA
NEW YORK — June 26, 2014 — Vringo, Inc. (NASDAQ: VRNG), a company engaged in the innovation, development and monetization of intellectual property and mobile technologies, today announced that its wholly owned subsidiary, Vringo Infrastructure, Inc., filed a patent infringement lawsuit against ZTE in Romania.
On June 23, 2014, Vringo Infrastructure, Inc. sued ZTE Corporation and its wholly owned subsidiary ZTE Romania SRL, ASBIS Romania SRL, Ilex Com SA, Dante International SRL, and SC TEOVLAD COM SRL in the Bucharest Tribunal Civil Section. The filings allege infringement of the Romanian part of European Patent 1,808,029. The patent in suit relates to the handover between different networks initiated by a mobile device. This patent has been declared essential to ETSI in connection with 4G LTE standards.
About Vringo, Inc.
Vringo, Inc. is engaged in the development and monetization of intellectual property worldwide. The Company's intellectual property portfolio consists of over 600 patents and patent applications covering telecom infrastructure, internet search and mobile technologies. The Company's patents and patent applications have been developed internally and acquired from third parties. For more information, visit: www.vringo.com.
Forward-Looking Statements
This press release includes forward-looking statements, which may be identified by words such as "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our inability to license and monetize our patents, including the outcome of the litigation against online search firms and other companies; our inability to monetize and recoup our investment with respect to patent assets that we acquire; our inability to develop and introduce new products and/or develop new intellectual property; new legislation, regulations or court rulings related to enforcing patents, that could harm our business and operating results; unexpected trends in the mobile phone and telecom infrastructure industries; our inability to raise additional capital to fund our combined operations and business plan; our inability to maintain the listing of our securities on a major securities exchange; the potential lack of market acceptance of our products; potential competition from other providers and products; our inability to retain key members of our management team; the future success of Infomedia and our ability to receive value from its stock; and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC on March 10, 2014. Vringo expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investors and Media:
Cliff Weinstein
Executive Vice President
Vringo, Inc.
646-532-6777
cweinstein@vringoinc.com
Edit your subscription | Unsubscribe
PRKR
http://www.streetinsider.com//images/ckuploads/pdf/2014/06/25/PRKR%20document.pdf
Also this tweet...
Daniel B. Ravicher ?@danravicher 7h
$PRKR adds Don Dunner of Finnegan Henderson to appeal team who won Uniloc appeal when judge had granted JMOL noninfringement for Microsoft.
Where have you been ?. What's the latest that you can tell us about W LA N
Thanks for the valuable info!
I use Fidelity
Thanks for that heads up. I do not know if I can put a trade order in though. My portfolio has a number assigned to the stock , not a symbol.
Nope, when I try only option I get is view lots.
So much for this Lotto! :-/
Good thing I only had 2 milly @ 0.0001
Do you put orange slices in yours?
Nice little Scalp you pulled this morning Beach!
ISR back in @ 3.01
ISR out @3.18. Looking to get back In after I check chart and news
ISR in @ 2.94
I got stopped out so AT it will probably run g/r now
Definately is hard to trade effectively and work a J.O.B. ! Looking forward to retirement and using to my advantage what I am learning now!
Oh I am sure we will all be watching! I will for sure!
PRKR
In @ 1.95. Seems to be consolidation for now. Power hour may show the true feeling of the market for this stock. Ya think?
OPK unusual volume Friday
OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares
By GuruFocus, June 20, 2014, 07:04:43 PM EDT
Dr. Frost has an excellent track record. He has successfully founded several pharmaceutical companies and overseen the development and commercialization of a multitude of others. He was chairman of the board of Key Pharmaceuticals from 1972 until it was acquired by Schering Plough in 1986. Frost was then chairman of the board of IVAX since 1987 until it was acquired by Teva ( TEVA ) in 2006. He then took over as chairman of the board of Teva Pharmaceutical. He also served as chairman of the board of directors of PROLOR, a development stage biopharmaceutical company that was purchased by OPKO in 2013. To name a few more, he previously served as a director for Continucare Corp, Northrop Grumman ( NOC ), Ideation Acquisition Corp, and as Governor and Co-Vice-Chairman of the American Stock Exchange.
Dr. Frost has a history of developing pharmaceutical companies. In the early 1970s he took over Key Pharmaceuticals with billionaire partner Michael Jaharis to develop generics and veterinary products. They sold the company to Schering-Plough in 1986. In 1987 Frost founded generic drug maker Ivax and sold it to Teva Pharmaceutical for $7.6 billion in 2005. OPKO Health is his next project.
OPKO Health was originally Cytoclonal Pharmaceutics and later changed to eXegenics. eXegenics was engaged in the research, creation, and development of new drugs for the treatment and prevention of cancer and infectious diseases. In late 2002 the company began winding down its drug discovery operations and had no revenue from 2003-2006. The company in its current form started in 2007 with the merger of eXegenics, Froptix, and Acuity Pharmaceuticals. Dr. Phillip Frost became the Chairman and CEO of the newly formed company.
Today OPKO is a multi-national pharmaceutical and diagnostics company built up through acquisitions over the years. It focuses on less crowded parts of the industry and purchases late stage development products with large market potential. Strategic investments are also made in companies for capital appreciation and product rights.
The first major revenue generating product, 4Kscore Test, recently hit the market in the United States and will launch in Europe in September. It is a point-of-care diagnostic system for prostate cancer testing, as well as for use in laboratory systems. The panel of markers included in the OPKO 4Kscore is the result of a decade of research by scientists in Europe and the U.S. Extensive studies have shown that it may reduce the number of unnecessary prostate biopsies by 50 percent or more, avoiding the frequent complications of pain, bleeding, and infection, which sometimes require hospitalization. In a recent investor presentation, OPKO said that the PSA (Prostate-Specific Antigen) market is 60 million tests globally. Currently in the U.S., sales equate to $395 per test.
The 4Kscore test is part of the point-of-care hardware system that will be able to produce laboratory-quality test results from a single finger-stick of blood in about 10 minutes, all at the doctor's office. The other tests under development are for the detection of low vitamin D, low testosterone, and Alzheimer's disease. The vision for this product is that it can be used as a fast diagnostic tool in every doctor's office.
The low vitamin D test is on track support the launch of the drug Rayaldy in the first quarter of 2016. It is currently in phase III and has U.S. patents protecting it through 2028. The drug is for patients with chronic kidney disease (CKD) in stage 3-4. There are currently 8 million CKD stage 3-4 patients in the United States. Rayaldy is expected to take a significant market share in the patients suffering from SHPT making it a potential $12 billion revenue opportunity. There are also three other drugs in phase III with a revenue potential of about an additional $6 billion. There also additional drugs in phase II and preclinical trials.
Through Frost's business savvy and medical industry connections, he has been slowly building a pharmaceutical powerhouse for what is likely his last project. Opkco is in control of the entire supply chain through diagnostics, research and development, manufacturing, and distribution. OPKO has been strategically buying medical businesses in Europe and Latin America to help build out its marketing and distribution channels.
Many of the assets that he has been buying were a bargain prices. Shareholders of PROLOR Biotech filed a lawsuit to because they thought the purchase price for the company was too low. PROLOR Biotech was purchased for $480 million last year. The main drug obtain in the deal was a more efficient hGH drug that is currently in phase III with a potential market size of $3.5 billion. The suit was recently dismissed. Another example of OPKO's successful bargain hunting is their purchase of the drug Rolapitant. Schering-Plough had to unload the drug during its merger with Merck in 2009. OPKO was able to purchase it for $2 million up front and potentially pay another $27 million if certain milestones were reached. A year later OPKO sold the rights to the drug to Tesaro ( TSRO ) for up to $121 million, including up-front payment and additional payments based on achievement of milestones. OPKO will also receive double digit royalties on sales and received a 10 percent equity position in Tesaro. Tesaro now has a $1.1 billion market cap and Rolapitant is now in phase III with a $1.5 billion market potential.
Dr. Frost also an avid investor of small companies and has taken many public. Many of his investments are in medical start-up companies that bring him back to his passion of medical research. OPKCO has a strategic investments portfolio controlled by Dr. Frost. It is said that he is a long-term investor that uses his influences to organize and manage. Some of the investments are listed on the company's website in the "Strategic Investments" section. They include: ARNO Therapeutics ( ARNI ), ChromaDex Corp ( CDXC ), Cocrystal Pharma (COCP), Neovasc (NVCN), Pharmsynthez (MIC:LIFE), RXi Pharmaceuticals (RXII), Senesco (private), and Zebra Biologics (private).
1403299582708.png
Dr. Frost is going to step down as Chairman of Teva Pharmaceuticals at the end of the year freeing up more time for him to work on OPKO. The Miami multi-billionaire has an excellent track record. He founded, developed, and sold two major drug companies, Key Pharmaceuticals and Ivax. Ivax was sold for $26 a share to Teva in 2005. Split adjusted, its IPO price was $0.38, providing a compounded annualized return of 26.5 percent. OPKO is his next venture. The stock closed at $4.50 in May of 2007 when the company was changed from eXegenics to Opkco and traded under the new symbol. It closed today at $9.23, an annualized return of about 11 percent compared to only about a 3.7 percent annualized gain for the S&P 500. Many of the large biopharmaceutical companies sell at a price-to-sales multiple between 4.5 and 10. At this time Ralaydy with its $12 billion potential, is projected to start selling in the beginning of 2016. If the drug only sells a quarter of its potential and the company trades at the bottom of the price-to-sales range, the stock would be worth $32.62 per share by then end of 2016. Those numbers are also ignoring the of the revenue potential from diagnostic equipment and other drugs in the pipeline, including three others in phase III and two in phase II. The stock has plenty of risk associated with it. Looking at the financial statements, the company is all promises with little revenue to show for it. Like other biotech stocks, one bad FDA announcement involving the trials could send the stock down by 20 percent, especially if it involves Rayaldy. This company is not a one-drug wonder. It has plenty of other revenue opportunities in the pipeline and continues to add to its arsenal with new acquisitions. I think this company could follow in the footsteps of Ivax and provide extraordinary gains.
The legendary investor, George Soros, has been accumulating OPKO shares. He is the largest shareholder of the gurus we follow. He initiated his position in the third quarter of 2013 and just bought 76.98 percent more in the first quarter of 2014. He now has 1,494,800 shares. You can follow him at GuruFocus to see how he manages his position.
1403299901019.png
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
Read more: http://www.nasdaq.com/article/opko-ceo-is-building-a-pharma-powerhouse-and-continuously-buying-shares-cm363788#ixzz35SvX5xTY
QEDN
QED Connect, Inc. Completes 40% Authorized Share Reduction
Jun 20, 2014
OTC Disclosure & News Service
-
QED Connect, Inc. Completes 40% Authorized Share Reduction
MANCHESTER, NH--(Marketwired - Jun 20, 2014) - Management of QED Connect, Inc. (OTC Pink: QEDN) (PINKSHEETS: QEDN) today announced that they have received official completion notice from the Secretary of State (SOS) of New York for the reduction of its authorized shares of common stock to 600,000,000 from 1,000,000,000. Additionally, the Series A preferred shares shall no longer have conversion rights to common shares. The amendment to the Articles of Incorporation that was filed with the SOS will be reflected in subsequent fillings. The web site for OTC Markets has been updated to reflect the current number of shares.
Additionally, the Company has initiated the process to have the DTC Chill lifted. A DTC chill is the suspension of certain DTC services with respect to an issuer's securities. It does not prevent trading of shares but requires shareholders to deposit the Company's shares manually. QED will provide continued updates to this process.
The Company's recently announced acquisition of Emerald Med Farms, Inc. is finalizing operations as it prepares to harvest the initial crop of plants (press release June 10th). Emerald Med Farms, Inc. is registered within the state of Nevada as a Domestic Corporation under NV Business ID# NV20141273899 and will have a dual registration to do business as a Foreign Corporation in the state of California. The Company is currently authorized to operate under the 180 day grace period while its registration is completed under the California SOS which is expected shortly.
About QED Connect, Inc.
QED Connect, Inc. is a holding company which makes acquisitions, investments, and enters into strategic business partnerships. The Company works with organizations that are looking for capital, management assistance, or help in reaching their target markets to realize their true potential. QED acquired StockProfile.com. In April 2014, the Company entered into an agreement to acquire Emerald Med Farms, Inc., a California based medical marijuana company (www.emeraldmedfarms.com). QED's business model helps to achieve its goals by expanding its overall revenue and profits potential through multiple market segments. www.qedconnect.com
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of QED to be materially different from those expressed or implied by such forward-looking statements. QED's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors.
For more information contact:
Tom Makmann
Tel: (603) 425-8933
Fax: (561) 764-6180
Email: info@qedconnect.com
KNDR
Kender Energy Announces Reverse Split
Jun 20, 2014
OTC Disclosure & News Service
-
Kender Energy Announces Reverse Split
CARSON CITY, NV and GENEVA, SWITZERLAND--(Marketwired - Jun 20, 2014) - Kender Energy, Inc. (OTC Pink: KNDR) (PINKSHEETS: KNDR) shareholders have voted for a reverse split of the Company's common stock resulting in a reduction of stock from about 257 million shares to about 514,000.
As of June 24, 2014 it is expected each 500 shares of Kender issued and outstanding common stock will automatically be combined and converted into one issued and outstanding share of common stock, par value $0.0001 per share. The reverse stock split is expected to affect all issued and outstanding shares of the Company's common stock, as well as common stock underlying stock options, stock appreciation rights, restricted stock units, warrants and convertible debentures that were outstanding immediately prior June 24, 2014.
Shareholders voting for the reverse split represented a majority of the current issued and outstanding holders, who entered into the written consent to effect the reverse split based on recommendations of the Board of Directors.
Sean Kelly, Director of Kender, said fractional shares will be rounded up to the nearest whole share. In addition, the Board recommended and shareholders consented to change the name of the Company to Bettworks Industries, Inc., giving the company a more agnostic name as the Company explores opportunities outside the energy sector.
Kender, a company based in Geneva, Switzerland, is a relative new solar energy firm developing proprietary prototypes of solar panels into full-scale solar energy production systems.
Kelly says the Board is determined to fix the ratio for the reverse stock split at 1-for-500 and trading on a post reverse split-adjusted basis on the OTC Markets. The date of the reverse split and name change is expected to be deemed effective by FINRA on June 23, 2014, Kelly explained, and trading under KNDR.D, a post-reverse split-adjusted basis on the OTC Markets, is set to begin as of the opening of trading on June 23, 2014. A symbol change will occur after 20 trading days from the effective date. The actual symbol change has not yet been determined by FINRA. The common stock will have a new CUSIP number upon the reverse stock split becoming effective.
While maintaining there can be no assurances, Kelly says the Kender board is attempting to rise the per share trading price of its common stock to improve investor confidence.
While the Board positions itself in the market place, Kender continues perfecting development of a solar panel system that allows, via a closed circuit of gas (usually helium), to create a heat exchange with sunlight and the air from the environment.
"The exchange generates the spinning of the helium gas in the closed circuit, propelling a turbine, which produces electricity in a 100% clean and renewable process," Kelly explains. The system's main advantage, Kelly says, is its' cost effective and efficient production; and it is modular.
Stockholders who would otherwise hold a fractional share of the Company's common stock will see their number of shares rounded to the next higher integer, according to the company's director.
The Kender board has alerted its stockholders holding shares held in book-entry form or through a bank, broker or other nominee, they are not required to take any action and will see the impact of the reverse stock split reflected in their accounts after the date the reverse split. Beneficial holders may contact their bank, broker or nominee for more information, Kelly said. He continued to advise that stockholders with shares held in certificate form may exchange their stock certificates for book-entry shares representing the shares of common stock resulting from the reverse stock split and they will receive a Letter of Transmittal as well as instructions for exchanging their certificates from the Company's exchange agent, Pacific Stock Transfer Inc.
Safe Harbor Statement
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plan, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Global Financial LLC, a Kender Energy, Inc. shareholder, is not responsible for the content of this news release; content of which was provided by the Kender Energy, Inc. Board of Directors to Global Financial LLC for public distribution.
CONTACT:
Sean Kelly
Director
Kender Energy, Inc.
Mob : +41 79 203 7124
Skype : sean.kelly
Email : sean.kelly.65@gmail.com
MDBX Moves fast on little volume
Medbox Launches Marijuana Dispensary Management Practice
Jun 23, 2014
OTC Disclosure & News Service
-
Medbox Launches Marijuana Dispensary Management Practice
Company Receives Provisional Approval to Operate Dispensary in Portland, OR;
Medbox to Provide Management and Regulatory Oversight for Dispensary
PR Newswire
LOS ANGELES, June 23, 2014
LOS ANGELES, June 23, 2014 /PRNewswire/ -- Medbox, Inc. (OTCQB: MDBX), a leader in providing lawful marijuana dispensary consulting services and patented dispensing systems to the alternative medicine industry, announced today that is it launching its marijuana dispensary management practice in Portland, OR. This business line, operated through the company's wholly owned Medbox Management Services, Inc. subsidiary, will provide necessary oversight services for dispensary operations in concert with a capable joint venture partner the company is currently in the process of sourcing, that will manage day-to-day activities at the dispensary. While the company has offered licensing consulting services since 2010, this will mark the first time the company has entered into a management contract to provide professional oversight services at a dispensary location.
Medbox recently received provisional approval to operate a medical marijuana dispensary in Portland and is in the process of preparing the dispensary for a cursory inspection by state officials for final approval with a grand opening scheduled in September of this year.
"Medbox is adapting its business model to capitalize on the demand from investors and individual states for Medbox to utilize its industry experience to professionally manage dispensary facilities. This opportunity represents a highly profitable revenue model for the Company and we are in the process of establishing operations in every state where marijuana is now legal. We will continue to seek to partner with affluent and high-pedigree clients on joint-venture partnerships in these states," stated Dr. Bruce Bedrick, CEO of Medbox, Inc. "As the country continues to march forward with sensible reform, we stand ready to supply the tools, software, consulting and management services that improve security, compliance and reporting," he added. "We look forward to expanding our presence nationwide and reaffirming our industry leadership position."
Nevada, Illinois Florida, New York, Minnesota, and Maryland have all recently passed medical marijuana legislation bringing the nationwide count to 23 states. Medbox has invited State officials from Nevada to see the future Medbox managed facility in Oregon, and will soon invite officials from other states as well.
About Medbox, Inc.
Medbox (http://www.medbox.com) is a leader in in providing lawful marijuana dispensary consulting services and patented secure dispensing systems to the alternative medicine industry. Headquartered in Los Angeles, CA, Medbox, through its wholly owned subsidiary, Medicine Dispensing Systems, offers its patented systems, software and consulting services to pharmacies, alternative medicine dispensaries and local governments in the U.S. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (www.vaporfection.com), the company offers an industry award winning medical vaporizer product. Medbox, through its newly established subsidiaries, is in development of the following ancillary services catered to the alternative medicine industry: merchant services and armored transport for cash deposits, cannabidiol research and development, real estate acquisitions and subsequent lease programs to alternative medicine dispensaries, and alternative medicine dispensary management services.
Forward-Looking Statements
The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.
Contact Information
Investor Relations:
Scott Greiper
Secure Strategy Group, LLC
sgreiper@securesg.com
212-333-0202
Medbox:
For more information on Medbox, please call (800) 762-1452.
SOURCE Medbox, Inc.
BYSD
Bayside Corp. Announces Additional Gross Sales Figures of Vault 51
Jun 23, 2014
OTC Disclosure & News Service
-
Bayside Corp. Announces Additional Gross Sales Figures of Vault 51
Vault 51 secure offline storage generates over $140,000 in initial gross sales revenue during the first ten days of its launch.
PR Newswire
DALLAS, June 23, 2014
DALLAS, June 23, 2014 /PRNewswire/ -- Bayside Corp. (BYSD) today announced additional gross sales revenue figures of Vault 51 (beta), operated by Bitcoinz USA a subsidiary corporation of Bayside Corp.
To continue, Bayside Corp. reported that the initial gross sales revenue of Vault 51 has slightly exceeded $140,000 over the course of the first ten days of its product launch. Additionally, the company also announced the launch of its online advertising plans, which kicks off today with an extensive Adwords campaign in order to generate higher visibility and sales for Vault 51.
Vault 51 is an offline storage system for Bitcoin users, which is represented by a Physical Bitcoin. The electronic Bitcoin is then stored off-line in a secured computer chip known as Vault 51 and embedded in a Physical Bitcoin, which is not connected to the internet. This process is also known as cold storage and is done to avoid hacking, loss, or theft. http://vault51.bitcoinzusa.com
About Bayside
Bayside Corp. is an American multinational corporation that manages multiple subsidiary companies engaged in a variety of business industries and sectors. At Bayside Corp. we believe that the future is now and that our efforts today will have a long lasting impact for generations to come. For additional information on the Company visit our website at: http://www.baysidecorp.com
Certain statements in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" All forward-looking statements are based on Bayside's current expectations, estimates, projections, beliefs and assumptions based on information available at the time the statement was made and in light of Bayside's experience and its perception of historical trends.
The forward-looking statement in this news release includes reference to: Bayside's ability to execute on its strategy and deliver strong results on behalf of its shareholders. Forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties; some that are similar to other related companies and some that are unique to our company. Bayside's actual results may differ materially from those expressed or implied by our forward-looking statements and you are cautioned not to place undue reliance on them.
CONTACT: Bayside Corporation, info@baysidecorp.com, 800-719-1310
SOURCE Bayside Corp.
BYSD
Bayside Corp. Announces Additional Gross Sales Figures of Vault 51
Jun 23, 2014
OTC Disclosure & News Service
-
Bayside Corp. Announces Additional Gross Sales Figures of Vault 51
Vault 51 secure offline storage generates over $140,000 in initial gross sales revenue during the first ten days of its launch.
PR Newswire
DALLAS, June 23, 2014
DALLAS, June 23, 2014 /PRNewswire/ -- Bayside Corp. (BYSD) today announced additional gross sales revenue figures of Vault 51 (beta), operated by Bitcoinz USA a subsidiary corporation of Bayside Corp.
To continue, Bayside Corp. reported that the initial gross sales revenue of Vault 51 has slightly exceeded $140,000 over the course of the first ten days of its product launch. Additionally, the company also announced the launch of its online advertising plans, which kicks off today with an extensive Adwords campaign in order to generate higher visibility and sales for Vault 51.
Vault 51 is an offline storage system for Bitcoin users, which is represented by a Physical Bitcoin. The electronic Bitcoin is then stored off-line in a secured computer chip known as Vault 51 and embedded in a Physical Bitcoin, which is not connected to the internet. This process is also known as cold storage and is done to avoid hacking, loss, or theft. http://vault51.bitcoinzusa.com
About Bayside
Bayside Corp. is an American multinational corporation that manages multiple subsidiary companies engaged in a variety of business industries and sectors. At Bayside Corp. we believe that the future is now and that our efforts today will have a long lasting impact for generations to come. For additional information on the Company visit our website at: http://www.baysidecorp.com
Certain statements in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" All forward-looking statements are based on Bayside's current expectations, estimates, projections, beliefs and assumptions based on information available at the time the statement was made and in light of Bayside's experience and its perception of historical trends.
The forward-looking statement in this news release includes reference to: Bayside's ability to execute on its strategy and deliver strong results on behalf of its shareholders. Forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties; some that are similar to other related companies and some that are unique to our company. Bayside's actual results may differ materially from those expressed or implied by our forward-looking statements and you are cautioned not to place undue reliance on them.
CONTACT: Bayside Corporation, info@baysidecorp.com, 800-719-1310
SOURCE Bayside Corp.
Good Morning ATS!
Doesn't stem have a conference call today?
Were you in before the gap this morning?
Bragger!!
You mean you can appeal an appeal?
Are you out JC?
What do you use then? Rabbits feet and a Ouija board?
IDGC
Up 80%
ID Global Corporation Obtains Licensing and Distribution Agreement for Green Rush(TM) Brand of Cannabis/Hemp Product Line
Jun 18, 2014
OTC Disclosure & News Service
-
CHICAGO, June 18, 2014 (GLOBE NEWSWIRE) -- ID Global Corp. (OTC:IDGC) is pleased to announce that it has obtained the exclusive worldwide licensing and distribution agreement from Corr Brands, Inc. (CBI) for GREEN RUSHâ„¢ Products. A new brand development division will be started by IDGC as the products are packaged for sale and IDGC will invoice all sales for GREEN RUSHâ„¢ Products in the marketplace.
Through the agreement IDGC is granted exclusive worldwide licensing and distribution rights through the year 2017 within retail channels including:
National, regional or independent chains;
Natural food stores;
Club stores;
Mass merchandising or drug store chains;
Gourmet or specialty outlets;
Department stores;
Food service industry and other institutional sales; and
Armed forces sales and outlets.
Sebastien DuFort, president and CEO stated, "This is a significant step for IDGC to enter the medical marijuana market with an established and trusted group. We have been in discussions with other strategic partners and affiliates to ensure we execute and take full advantage of this opportunity. More details about the partnerships and roll out plans will follow."
About Corr Brands, Inc.
Corr Brands, Inc. is an Illinois corporation founded in 1978 as the holding company for intellectual property (IP) of Robert J. Corr and his family. The flagship brands are Ginseng Rush and Apple Rush brands, but also include Green Rush and Hard Rush. The Corr family recently licensed the Apple Rush and Ginseng Rush Brands, as well as sold controlling interest in Apple Rush Company, Inc. (APRU) to the California-based LiveWire Ergogenics Inc. (LVVV), also a public company.
CBI is a long lived company that over the years has licensed its IP to various third party concerns. The new mode of operation is to minimize external influences and concentrate efforts in a targeted, low overhead manufacturing and marketing endeavor.
About ID Global Corporation
ID Global Corporation (IDGC) is a diversified holdings company with a focus on emerging and middle market investment opportunities in North America. IDGC seeks, through debt and equity investments, minority positions as well controlling interests in established companies and special situation start-ups.
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of ID Global Corporation and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
CONTACT: ID Global Corporation
Attn: Sebastien DuFort
230 W. Monroe St., Ste. 310
Chicago, Illinois 60606
6305323625
Sdufort68@gmail.com
T12 for information requested by NASDAQ
SNTA
Why A Short Covering Rally Might Come for Synta (SNTA) Stock - Tale of the Tape
By Zacks.com, June 16, 2014, 11:00:04 AM EDT
A A A
Vote up
Comment
More Sharing ServicesShare | Share on facebook Share on twitter Share on email Share on print Subscribe
Many investors appear to be quite bearish on Synta Pharmaceuticals Corp. ( SNTA ) , especially if you look at the percentage of the float that is sold short for this stock. Currently, 23.85% of the float is sold short, suggesting an extreme level of bearishness for SNTA.
While investors might be piling up against this stock for any number of reasons, it is important to note that SNTA has seen some weakness as of late, as the security hasn't been able to get into positive territory over the past four weeks, losing 1.75% in the time frame.
Better Trading Ahead?
While the short interest and the recent performance are certainly troubling, there is reason to be optimistic on this stock. Recent earnings estimate activity has actually been quite positive as of late, even in the face of such widespread pessimism.
Thanks to these rising estimates, we actually have a Zacks Rank #2 (Buy) on SNTA, so we clearly don't believe in the negativity surrounding this firm. After all, it is hard not to be at least a little optimistic on the short term when you consider that 4 estimates have moved higher in the past 60 days compared to none lower in the same time frame, while the consensus has also increased.
Given this, a short-covering rally is certainly in the cards for SNTA stock, especially if investors embrace the positive earnings estimate revision picture, suggesting that SNTA could definitely move higher in the weeks ahead.
Read more: http://www.nasdaq.com/article/why-a-short-covering-rally-might-come-for-synta-snta-stock-tale-of-the-tape-cm362002#ixzz34wIz9EdJ
TDEY
New Acquisitions and Business Developmwnt
Jun 17, 2014
OTC Disclosure & News Service
Grapevine, TX
This release includes additional documents. Select the link(s) below to view.
TDEY PR For June16 2014 FINAL3.pdf
Copyright © 2014 OTC Markets. All Rights Reserved
FOGC
Manzo Pharmaceuticals announces the release of its newest product Tummy Relief a natural colic remedy for babies
Jun 17, 2014
OTC Disclosure & News Service
-
Manzo Pharmaceuticals announces the release of its newest product Tummy Relief a natural colic remedy for babies
PR Newswire
MILFORD, Pa., June 17, 2014
MILFORD, Pa., June 17, 2014 /PRNewswire/ -- Fortune Oil & Gas, Inc. (OTCPink: FOGC), today announced that its wholly owned subsidiary, Manzo Pharmaceuticals has released its first retail product to be available to the public. It is a remedy for babies with excess gas, which often causes a condition known as colic. The product, called Manzo's Tummy Relief, is currently available for purchase on Amazon.com.
Colic is defined as periods of continuous crying for more than three hours per day, and although many other ailments can cause the condition, stomach and intestinal gas is often the culprit. Manzo's solution is a natural, safe and effective liquid given to the infant in the form of drops. Compared to competitors, Manzo's solution contains larger amounts of the effective ingredients, costs less, does not contain many unnatural or even harmful additives that other remedies do, and it comes in a unique spill proof bottle that avoids those frustrating spills and allows for more efficient use of the product with less waste. With competitor's products, it is difficult to get all of the liquid out of the bottle because of the design of the packaging causing waste, and costing consumers more money, but with Manzo's design, consumers can use every last drop in the bottle saving time and money.
The company's CEO, Kenneth Manzo developed the product and designed the packaging with more than his expertise in pharmaceuticals in mind. As a parent himself he knows how inefficient and expensive these types of remedies can be. "I wanted to offer parents a solution that actually worked well and didn't break the bank. New parents have a lot of things to stress about, especially when their baby has colic. If we can give peace of mind to even one household at an affordable price, it was worth it. I think parents will be clamoring for bottles of Tummy Relief because frankly, there is nothing available to consumers that is as good," explained Mr. Manzo. You can find out all about Tummy Relief on the product website at www.tummy-relief.com.
Manzo also wanted to let shareholders know that the company has a lot of exciting developments lined up. Most immediate is that the company is preparing to file for a name change and hopes to have that done within the next week or two. This is a critical step in the overall strategy because once completed, the company will be ready to really begin utilizing the media to get its message out there, so it is shaping up to be a very exciting summer for Manzo Pharmaceuticals.
About Fortune Oil & Gas, Inc.
Fortune Oil & Gas, Inc. owns and operates Manzo Pharmaceuticals, a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER: ?This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
SOURCE Fortune Oil & Gas, Inc.
Looks like your theory that when clay post a chart iStock automatically goes down the next day. Doesn't seem that way does it 38% up! I think somebody owes Clay an apology!
MLCG
up 74% on 1.3 mil shs
ILIV
up 17% on 24 mil shs
KGET
moving up 17% on 6.1 mil shs